30Jan 2022
The pan‐JAK inhibitor delgocitinib in a cream formulation demonstrates dose‐response in chronic hand eczema in a 16‐week randomised phase 2b trial

The pan‐JAK inhibitor delgocitinib in a cream formulation demonstrates dose‐response in chronic hand eczema in a 16‐week randomised phase 2b trial

Chronic hand eczema (CHE) is a burdensome disease, and new well‐documented, safe, and efficacious treatments are warranted. In a recent CHE phase 2a trial, the pan‐Janus kinase (JAK) inhibitor delgocitinib in an ointment formulation was found to be efficacious and well‐tolerated. This trial assessed the dose‐response, efficacy, and safety of delgocitinib cream in CHE. In this double‐blind, phase 2b dose‐ranging trial, adults with CHE and a recent history of inadequate response or contraindication to topical corticosteroids were randomized to delgocitinib cream 1, 3, 8, 20 mg/g or vehicle treatment twice daily for 16 weeks...

  • #dermatology

Like

Save

Share